Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Fiche publication
Date publication
janvier 2019
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARCHINI Antonio, Dr DAEFFLER Laurent
Tous les auteurs :
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J
Lien Pubmed
Résumé
Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a "cold" immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.
Mots clés
H-1PV, checkpoint blockade, combination therapy, immunogenic cell death, immunotherapy, oncolytic viruses, tumor microenvironment
Référence
Front Immunol. 2019 ;10:1848